Hologic stock (US4364401012): Analyst focus starts the week after latest earnings miss revenue consensus

Hologic opens the trading week on Nasdaq in the United States with investor attention still centered on its most recent quarter, where the medical technology group delivered modest earnings growth but slightly undershot Wall Street revenue expectations.

Hologic began the new week on the Nasdaq in the United States with investors still digesting its most recent quarterly figures, which showed modest top-line growth but revenue that fell short of analyst expectations, keeping attention on how the stock is being viewed by research houses in the current environment, according to MarketBeat as of 05/02/2026.

The women’s health-focused medical technology group, headquartered in Marlborough, Massachusetts, reported quarterly revenue of USD 1.05 billion for the period ended 03/30/2026, an increase of 2.5% year-over-year but below the roughly USD 1.07 billion consensus estimate compiled by analysts, according to MarketBeat data as of 05/02/2026. With a trailing earnings per share figure of USD 2.40 and a price-earnings ratio of about 31.7 as of early May 2026, the company is trading at a valuation that keeps it firmly in focus for United States healthcare investors tracking the broader Nasdaq healthcare space.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Hologic
• Sector/industry: Medical technology, women’s health diagnostics and surgical solutions
• Headquarters/country: Marlborough, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Diagnostic systems and assays, breast and skeletal health imaging, gynecologic surgical products
• Home exchange/listing venue: Nasdaq (HOLX)
• Trading currency: USD

Hologic: core business model

Hologic generates most of its revenue by supplying specialized diagnostics platforms, imaging systems and related consumables focused on women’s health, with recurring test volumes and equipment replacement cycles underpinning its long-term cash flows.

What banks and research houses say about Hologic

Analyst coverage for Hologic in the United States remains centered on how the company balances steady core diagnostic growth with the normalization of pandemic-related testing volumes after its latest quarter modestly lagged revenue consensus, based on data compiled by MarketBeat as of 05/02/2026. According to MarketBeat’s earnings overview as of that date, Hologic’s quarterly revenue of USD 1.05 billion came in slightly below the roughly USD 1.07 billion average analyst estimate, a gap that keeps the focus on execution in its diagnostics and imaging franchises rather than on large-scale guidance revisions.

The same MarketBeat summary shows that, with trailing earnings per share of USD 2.40 and a price-earnings ratio near 31.7 as of early May 2026, the stock’s valuation sits in a range where small changes in earnings expectations can have an outsized impact on the share price, encouraging investors to track research updates from major United States banks that follow medical technology names. In this context, the combination of slightly softer-than-expected revenue, continued profitability and a still-elevated multiple frames the discussion for analysts as they refine their models in the months ahead.

Conclusion

The start of the week finds Hologic’s stock on Nasdaq shaped by its most recent quarterly print, where revenue grew modestly but fell short of Wall Street expectations, leaving investors focused on how management can convert its women’s health portfolio into steadier top-line expansion. The analyst lens is currently trained on the balance between valuation, with a trailing price-earnings ratio above 30, and the company’s ability to defend margins and deliver incremental growth in diagnostics, imaging and surgical products in the United States and abroad. How these elements evolve over the next few quarters will likely influence both the tone of future research coverage and the stock’s position within diversified healthcare portfolios.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.